SORBS2 and ovarian cancer: Moreover, the expression of SORBS2 in late stage ovarian cancer patients (FIGO stages III and IV) was also significantly reduced compared with early stage ovarian cancer patients (FIGO stages I and II) in Gilks’ dataset and Yoshihara’s dataset (Additional file 2: Figure S2b) while no significant difference was observed in the expression of BTF3, CIRBP, and MEX3D between primary and metastatic ovarian tissues in public datasets (Additional file 2: Figure S3a–c).